IOSP · XBRL financial data
Innospec financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (IOSP's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 1,193 | 1,483 | 1,964 | 1,949 | 1,845 | 1,778 |
| Cost of goods and services sold | 850 | 1,049 | 1,377 | 1,358 | 1,303 | 1,286 |
| Gross profit | 343 | 435 | 587 | 591 | 543 | 492 |
| Research and development | 31 | 37 | 39 | 42 | 48 | 51 |
| Selling, general and administrative | 237 | 267 | 361 | 388 | 314 | 285 |
| Total operating expenses | 309 | 303 | 399 | 430 | 365 | 363 |
| Operating income (loss) | 34 | 132 | 187 | 162 | 178 | 130 |
| Interest expense | 1 | 0 | 0 | 0 | 0 | 0 |
| Other income (expense) | 8 | 4 | (2) | 11 | 10 | (1) |
| Income tax expense (benefit) | 11 | 41 | 52 | 35 | 6 | 22 |
| Earnings per share, basic USD per share | 1.17 | 3.78 | 5.37 | 5.60 | 1.43 | 4.69 |
| Earnings per share, diluted USD per share | 1.16 | 3.75 | 5.32 | 5.56 | 1.42 | 4.67 |
| Weighted average shares, basic millions of shares | 25 | 25 | 25 | 25 | 25 | 25 |
| Weighted average shares, diluted millions of shares | 25 | 25 | 25 | 25 | 25 | 25 |
Balance sheet
CSVFiscal years (IOSP's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 105 | 142 | 147 | 204 | 289 | 293 |
| Inventory | 220 | 278 | 373 | 300 | 301 | 329 |
| Total current assets | 566 | 728 | 873 | 886 | 957 | 1,005 |
| Property and equipment, net | 211 | 214 | 221 | 268 | 270 | 286 |
| Right-of-use asset | 40 | 35 | 45 | 45 | 45 | 53 |
| Goodwill | 371 | 364 | 359 | 399 | 383 | 399 |
| Total assets | 1,397 | 1,571 | 1,604 | 1,707 | 1,735 | 1,832 |
| Accounts payable | 99 | 149 | 165 | 164 | 164 | 175 |
| Accrued liabilities | 130 | 167 | 203 | 186 | 169 | 152 |
| Current portion of long-term debt | 0 | — | — | — | — | — |
| Total current liabilities | 252 | 337 | 406 | 372 | 371 | 360 |
| Long-term debt | 0 | — | — | — | — | — |
| Lease liability, non-current | 29 | 23 | 31 | 32 | 31 | 37 |
| Total liabilities | — | 538 | 563 | 558 | 519 | 500 |
| Retained earnings | 759 | 823 | 924 | 1,028 | 1,025 | 1,099 |
| Total stockholders' equity | 944 | 1,032 | 1,038 | 1,147 | 1,211 | 1,326 |
| Total liabilities and equity | 1,397 | 1,571 | 1,604 | 1,707 | 1,735 | 1,832 |
| Common shares outstanding (cover page) millions of shares | 25 | 25 | 25 | 25 | 25 | 25 |
Cash flows
CSVFiscal years (IOSP's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 6 | 4 | 7 | 8 | 9 | 8 |
| Depreciation and amortization | 46 | 43 | 40 | 39 | 44 | 44 |
| Net cash from operating activities | 146 | 93 | 82 | 207 | 185 | 138 |
| Net cash from investing activities | (30) | (36) | (42) | (112) | (62) | (75) |
| Share repurchases | 2 | 1 | 6 | 1 | 1 | 24 |
| Dividends paid | 26 | 29 | 32 | 35 | 39 | 42 |
| Net cash from financing activities | (87) | (20) | (34) | (39) | (35) | (64) |
| Net change in cash | 30 | 37 | 5 | 57 | 86 | 3 |
Compare with peers
SIC 2800 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2800 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Innospec | 252 | 474 | not reported | 24.6M | — | 10-QSep 30, 2026 |
| Ingevity | 97 | 314 | (14)* | 34.4M | 7.1 quarters | 10-QJun 30, 2026 |
| Chemours | 671 | 1,591 | 158* | 150.5M | — | 10-QJun 30, 2026 |
| Huntsman | 359 | 1,717 | not reported | 175.3M | — | 10-QSep 30, 2026 |
| Ecovyst | 88 | 250 | 34* | 109.5M | — | 10-QJun 30, 2026 |
| Perimeter Solutions | 83 | 214 | (0.7)* | 163.7M | 126.6 quarters | 10-QJun 30, 2026 |
| OLIN | 215 | 1,748 | 110* | 114.0M | — | 10-QSep 30, 2026 |
| Solstice Advanced Materials | 750 | 1,148 | 262* | 158.8M | — | 10-QJun 30, 2026 |
| Balchem | 66 | 291 | 70* | 31.8M | — | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.